Stem Cell Transplantation to Treat Myeloma Patients Highlighted in Studies
Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai in New York, and Navneet Majhail,…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Leisure-Time Physical Activity Associated with Lower Cancer Risk, Including Myeloma
Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of…
Selinexor Shows Promising Clinical Results in Advanced Solid Tumors, Paving Way for Future Myeloma Trials
Newton, Massachusetts-based Karyopharm Therapeutics has published the results from its Phase 1 trial of selinexor (KPT-330) in patients with advanced solid tumors in the…
‘Moving Mountains for Multiple Myeloma’ Hikes Grand Canyon to Raise Research Money
Three organizations — CURE Media Group, Multiple Myeloma Research Foundation (MMRF) and Takeda Oncology — joined together in the Moving Mountains for Multiple…
BMS, AbbVie Announce EC Approval of Empliciti For Multiple Myeloma
Bristol-Myers Squibb (BMS) Company and AbbVie have announced that the European Commission (EC) has approved Empliciti™ (elotuzumab) for the treatment of multiple…
ICER Analyzes Cost and Value of Drugs Used to Treat Multiple Myeloma in New Report
The Institute for Clinical and Economic Review (ICER), an independent nonprofit based in Boston that analyzes the value of drugs and other medical services, has released a…
